- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02418897
Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis
Does Abnormal Neuromuscular Junction Function Play a Role in the Pathogenesis of Motor Fatigue in Women With Multiple Sclerosis?
Study Overview
Status
Conditions
Detailed Description
The investigators will recruit 20 women with multiple sclerosis (MS) and fatigue and 10 normal controls with no identified causes of fatigue (no history of thyroid disease, anemia, liver disease, kidney disease, myasthenia gravis, and no major fatigue inducing medications). We will include MS patients with fatigue severity scale of ≥5. Patients with sleep disorders or significant depression will be excluded based on history, Epworth Sleepiness scale, and Beck's Inventory of Depression Scale. The study will include two clinic visits and a one-study visit. After informed consent is obtained (English and Spanish forms will be available), the following will be done during the study visit 1:
Neurological examination: Using handgrip dynamometer of the dominant hand.
- Maximum voluntary isometric contraction force (MVIC) of the handgrip; two contractions of as long as 5 seconds each.
- Single 30 seconds sustained maximal contraction of the handgrip to assess static fatigue.
- Series of brief maximal contraction over 30 seconds, Contractions will be timed at one contraction per second.
- Expanded Disability Status Scale (EDSS
- Fatigue severity scale (FSS) and modified fatigue impact scale (MFIS)
- Epworth Sleepiness scale for screening for sleep disorders.
- Beck's Inventory of Depression Scale for screening for depression. Clinic visit 2: The clinic visit 2 will be conducted 5-30 days after the clinic visit 1
Neurological examination: Using handgrip dynamometer of the dominant hand.
- Maximum voluntary isometric contraction force (MVIC) of the handgrip; two contractions of as long as 5 seconds each.
- Single 30 seconds sustained maximal contraction of the handgrip to assess static fatigue.
- Series of brief maximal contraction over 30 seconds, Contractions will be timed at one per second.
- Fatigue severity scale (FSS) and modified fatigue impact scale (MFIS)
Study Visit 3:
Electromyography (EMG) and SFEMG (Single Fiber Electromyography) of the extensor digitorum communis muscle (forearm muscle) will be performed on all women with fatigue and healthy controls at the TTUHSC electrophysiology lab to evaluate for NMJ abnormalities. The mean consecutive difference (MCD) of 20 pairs of single muscle fiber potentials will be collected using SFEMG from each of the 20 women with multiple sclerosis and fatigue and will be compared to MCD of 200 pair potentials from our recruited 10 normal control subjects and also to the previously published normative data.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79430
- Texas Tech University Health Sciences Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion Criteria for MS Group (20 women)
- Patients with relapsing remitting multiple sclerosis.
- Age 18 to 65 years
- Diagnosed with motor fatigue in multiple sclerosis > 6 weeks. Motor fatigue equates to muscle fatigue due to physical exertion and is alleviated with rest and associated with fatigability.
- Has a fatigue severity scale score (FSS) of ≥5.
- Ambulatory with Expanded Disability Status Scale score (EDSS) 1.5 -6.5.
Inclusion Criteria for Control Group (10 women)
- Female with no history of multiple sclerosis and no complaint of fatigue
- Age 18 to 65 years
Exclusion Criteria:
- Patients with MS exacerbation or corticosteroid treatment within one month before the study.
Patients with history or current diagnosis of:
- Untreated thyroid disease,
- Untreated vitamin D deficiency,
- pregnancy,
- taking over the counter energy booster in the last 1 week,
- taking medication that will improve the function of the neuromuscular junction (i.e. pyridostigmine, steroid, rituximab, mycophenolate mofetil, azathioprine),
- myasthenia gravis,
- symptoms or history of polyneuropathy involving the upper extremities,
- myopathy,
- symptoms or history suggestive of C7, C 8 radiculopathy,
- motor neuron disease,
- polio,
- chronic inflammatory demyelinating polyneuropathy,
- Guillain-Barre syndrome,
- radial nerve palsy,
- sleep disorders (Epworth Sleepiness scale> 10 ), or
- significant depression ( Beck's Inventory of Depression Scale >17)
- Taking major fatigue inducing medications. (e.g. Narcotics, and Sedatives)
- Taking anticoagulation therapy. (e.g. warfarin and heparin)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with abnormal Jitter.
Time Frame: 8 months
|
Single fiber electromyography (SFEMG) is used to measure the variation between firing of adjacent muscle fibers and to detect prolonged abnormal jitter.
The two criteria that the investigator will use to demonstrate abnormal neuromuscular Junction function are the 10% of pairs with abnormal jitter or abnormal mean jitter value of the 20 pairs .
The 95% confidence limit of all individual measurements has been used as upper limit of what is considered normal.
For extensor digitorum communis (EDC), the 95% confidence limit of jitter in individual pair mean consecutive difference (MCD) is 49 microseconds (MCD of individual pair is 30.6+/-9.2 micros) and the 95% confidence limit of jitter (mean MCD) per study is 38.1 microseconds (MCD per study is 30.7+/-3.7 micros).
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Score of fatigue (Fatigue severity scale (FSS) and modified fatigue impact scale (MFIS))
Time Frame: 8 months
|
8 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ahmed M Eldokla, MD, Texas Tech University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L15-098
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States